Kallum Titchmarsh
Stock Analyst at Morgan Stanley
(2.60)
# 2,840
Out of 4,455 analysts
163
Total ratings
46.2%
Success rate
2.1%
Average return
Main Sectors:
Stocks Rated by Kallum Titchmarsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Upgraded: Buy | $185 | $215.75 | -14.25% | 5 | Jun 18, 2026 | |
| IQV IQVIA Holdings | Downgraded: Hold | $225 | $191.14 | +17.71% | 4 | Jun 18, 2026 | |
| STVN Stevanato Group | Maintained: Hold | $19 | $17.84 | +6.50% | 9 | Jun 10, 2026 | |
| MMED MiniMed Group | Maintained: Buy | $19 | $14.24 | +33.43% | 2 | Jun 5, 2026 | |
| WST West Pharmaceutical Services | Rated: Hold | $315 → $325 | $350.85 | -7.37% | 8 | May 29, 2026 | |
| A Agilent Technologies | Reiterated: Buy | $160 | $136.01 | +17.64% | 5 | May 28, 2026 | |
| GH Guardant Health | Maintained: Buy | $130 | $149.22 | -12.88% | 5 | May 27, 2026 | |
| HTFL HeartFlow | Maintained: Hold | $35 | $35.65 | -1.82% | 1 | May 15, 2026 | |
| MTD Mettler-Toledo International | Rated: Hold | $1,475 → $1,275 | $1,263.75 | +0.89% | 3 | May 12, 2026 | |
| VCYT Veracyte | Maintained: Sell | $37 | $60.49 | -38.83% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $250 | $261.91 | -4.55% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $10 → $9 | $13.02 | -30.88% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 → $18 | $20.96 | -14.12% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $22 | $36.75 | -40.14% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $5.5 | $4.48 | +22.77% | 2 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $60 | $65.92 | -8.98% | 5 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 | $56.14 | +24.69% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $350 | $374.41 | -6.52% | 3 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $670 → $620 | $513.03 | +20.85% | 3 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $270 → $184 | $196.19 | -6.19% | 5 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $10.28 | -2.72% | 1 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 → $68 | $86.25 | -21.16% | 6 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $182 | $45.72 | +298.08% | 12 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $130 → $160 | $118.89 | n/a | 15 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $15 | $3.49 | n/a | 11 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $4.46 | n/a | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $17.33 | n/a | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $260 | $316.63 | n/a | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 → $11 | $9.30 | n/a | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $5.69 | n/a | 14 | Dec 3, 2024 |
Charles River Laboratories International
Jun 18, 2026
Upgraded: Buy
Price Target: $185
Current: $215.75
Upside: -14.25%
IQVIA Holdings
Jun 18, 2026
Downgraded: Hold
Price Target: $225
Current: $191.14
Upside: +17.71%
Stevanato Group
Jun 10, 2026
Maintained: Hold
Price Target: $19
Current: $17.84
Upside: +6.50%
MiniMed Group
Jun 5, 2026
Maintained: Buy
Price Target: $19
Current: $14.24
Upside: +33.43%
West Pharmaceutical Services
May 29, 2026
Rated: Hold
Price Target: $315 → $325
Current: $350.85
Upside: -7.37%
Agilent Technologies
May 28, 2026
Reiterated: Buy
Price Target: $160
Current: $136.01
Upside: +17.64%
Guardant Health
May 27, 2026
Maintained: Buy
Price Target: $130
Current: $149.22
Upside: -12.88%
HeartFlow
May 15, 2026
Maintained: Hold
Price Target: $35
Current: $35.65
Upside: -1.82%
Mettler-Toledo International
May 12, 2026
Rated: Hold
Price Target: $1,475 → $1,275
Current: $1,263.75
Upside: +0.89%
Veracyte
May 12, 2026
Maintained: Sell
Price Target: $37
Current: $60.49
Upside: -38.83%
May 12, 2026
Maintained: Buy
Price Target: $250
Current: $261.91
Upside: -4.55%
May 12, 2026
Rated: Hold
Price Target: $10 → $9
Current: $13.02
Upside: -30.88%
May 12, 2026
Maintained: Hold
Price Target: $21 → $18
Current: $20.96
Upside: -14.12%
May 12, 2026
Maintained: Hold
Price Target: $20 → $22
Current: $36.75
Upside: -40.14%
May 12, 2026
Rated: Hold
Price Target: $6 → $5.5
Current: $4.48
Upside: +22.77%
May 12, 2026
Maintained: Hold
Price Target: $60
Current: $65.92
Upside: -8.98%
May 12, 2026
Maintained: Buy
Price Target: $70
Current: $56.14
Upside: +24.69%
May 5, 2026
Maintained: Hold
Price Target: $350
Current: $374.41
Upside: -6.52%
Apr 27, 2026
Rated: Buy
Price Target: $670 → $620
Current: $513.03
Upside: +20.85%
Apr 23, 2026
Rated: Buy
Price Target: $270 → $184
Current: $196.19
Upside: -6.19%
Feb 13, 2026
Maintained: Hold
Price Target: $10
Current: $10.28
Upside: -2.72%
Jul 15, 2025
Maintained: Buy
Price Target: $100 → $68
Current: $86.25
Upside: -21.16%
Jul 15, 2025
Maintained: Buy
Price Target: $200 → $182
Current: $45.72
Upside: +298.08%
Jun 11, 2025
Maintained: Buy
Price Target: $130 → $160
Current: $118.89
Upside: n/a
May 20, 2025
Maintained: Hold
Price Target: $20 → $15
Current: $3.49
Upside: n/a
May 9, 2025
Maintained: Hold
Price Target: $10
Current: $4.46
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $19
Current: $17.33
Upside: n/a
Apr 24, 2025
Maintained: Hold
Price Target: $260
Current: $316.63
Upside: n/a
Feb 27, 2025
Maintained: Hold
Price Target: $10 → $11
Current: $9.30
Upside: n/a
Dec 3, 2024
Maintained: Hold
Price Target: $5 → $4
Current: $5.69
Upside: n/a